The global cancer therapeutics and biotherapeutics market size is expected to reach around US$ 339.44 billion by 2030 from US$ 161.76 billion in 2021 and is expected to grow at an impressive double-digit rate of 8.6% from 2022 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global cancer therapeutics and biotherapeutics market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 180+ Pages Research Report (Including latest research).
- Provide chapter-wise guidance on request 2022 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Precedence Research methodology.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1657
Report Scope of the Cancer Therapeutics and Biotherapeutics Market
| Report Coverage | Details |
| Market Size by 2030 | USD 339.44 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 8.6% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
Report Highlights
- On the basis of application, lung cancer segment holds the largest market share in the global cancer therapeutics and biotherapeutics market. The lung cancer is considered as highly risky cancer type all over the world. Thus, this is driving the growth of the segment.
- On the basis of top selling drugs, Revlimid segment holds the largest market share in the global cancer therapeutics and biotherapeutics market. The Revlimid is a drug that is used to treat a variety of malignancies. This medication extends the life of cancer patients.
Market Dynamics
Drivers
Growing prevalence of cancer
The cancer is considered as the biggest cause of death globally, with approximately 10 million fatalities expected in 2020, for almost one in every six deaths. The breast cancer, prostate cancer, and lung cancer are common types of cancer. To curb these statistics of death due to cancer, the cancer therapeutics and biotherapeutics are adopted on a large scale. Thus, growing prevalence of cancer is driving the growth of the cancer therapeutics and biotherapeutics market.
Restraints
Risks associated with anti-cancer drugs
The cancer therapeutics and biotherapeutics sometimes can cause complications for the cancer patients. The cancer drugs and medications are not suitable for everyone. Sometimes these can cause adverse effects on the patient body. To avoid such complications, doctors and healthcare practitioners are avoiding the usage of the cancer therapeutics and biotherapeutics. As a result, risks associated with anti-cancer drugs are restricting the growth of the global cancer therapeutics and biotherapeutics market over the forecast period. Moreover, the expansion of the cancer therapeutics and biotherapeutics market is expected in near future due to launch of new products in the market.
Opportunities
Growing geriatric population
The population of old people is growing at a rapid pace. The old people are more vulnerable to the cancer disorders. The old women mostly face problems of breast cancer. To treat such diseases, the healthcare practitioners and doctors are using cancer therapeutics and biotherapeutics on a large scale. The cancer therapeutics and biotherapeutics help geriatric population to boost their immune system. As a result, growing geriatric population is creating lucrative opportunities for the growth of the cancer therapeutics and biotherapeutics market.
Challenges
Lack of resources for the development of cancer therapeutics and biotherapeutics
The developing and underdeveloped countries does not have enough resources for the development of cancer therapeutics and biotherapeutics. Even healthcare sector is not so developed which can help in the growth of the cancer therapeutics and biotherapeutics market. This is having adverse effects on the growth of the market. As a result, lack of resources for the development of cancer therapeutics and biotherapeutics is a major challenge for the cancer therapeutics and biotherapeutics market growth over the forecast period.
Research Methodology
A unique research methodology has been utilized to conduct comprehensive research on the growth of the global cancer therapeutics and biotherapeutics market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the draw conclusions. Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global cancer therapeutics and biotherapeutics market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimates the future prospects of the global market more reliable and accurate.
Why should you invest in this report?
If you are aiming to enter the global cancer therapeutics and biotherapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cancer therapeutics and biotherapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global cancer therapeutics and biotherapeutics market include:
- Amgen Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- ELI Lilly and Company
- Hoffmann-La Roche AG
- EnGeneIC Ltd
- Merck & Co Inc.
- Novartis
- Pfizer Inc.
- Johnson & Johnson
Market Segmentation:
By Application
- Blood Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Breast Cancer
- Cervical Cancer
- Head and Neck Cancer
- Giloblastoma
- Malignant Meningioma
- Mesothelioma
- Melanoma
- Others
By Top Selling Drugs
- Revlimid
- Avastin
- Herceptin
- Rituxan
- Opdivo
- Gleevec
- Velcade
- Imbruvica
- Ibrance
- Zytiga
- Alimta
- Xtandi
- Tarceva
- Perjeta
- Termodar
- Others
By Product Type
- Chemotherapy
- Radiation Therapy
- Hormone Therapy
- Biotherapy
- Others
By End User
- Consumption (Sales)
- Household
- Hospital
Regional Analysis:
The geographical analysis of the global cancer therapeutics and biotherapeutics market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global cancer therapeutics and biotherapeutics Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global cancer therapeutics and biotherapeutics market in 2030?
- What is the expected CAGR for the cancer therapeutics and biotherapeutics market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global cancer therapeutics and biotherapeutics market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Therapeutics and Biotherapeutics Market
5.1. COVID-19 Landscape: Cancer Therapeutics and Biotherapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Therapeutics and Biotherapeutics Market, By Product
8.1. Cancer Therapeutics and Biotherapeutics Market, by Product Type, 2022-2030
8.1.1. Chemotherapy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Radiation Therapy
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Hormone Therapy
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Biotherapy
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cancer Therapeutics and Biotherapeutics Market, By End User
9.1. Cancer Therapeutics and Biotherapeutics Market, by End User, 2022-2030
9.1.1. Consumption (Sales)
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Household
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hospital
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cancer Therapeutics and Biotherapeutics Market, By Application Type
10.1. Cancer Therapeutics and Biotherapeutics Market, by Application Type, 2022-2030
10.1.1. Blood Cancer
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Lung Cancer
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Colorectal Cancer
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Prostate Cancer
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Breast Cancer
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Cervical Cancer
10.1.6.1. Market Revenue and Forecast (2017-2030)
10.1.7. Head and Neck Cancer
10.1.7.1. Market Revenue and Forecast (2017-2030)
10.1.8. Giloblastoma
10.1.8.1. Market Revenue and Forecast (2017-2030)
10.1.9. Malignant Meningioma
10.1.9.1. Market Revenue and Forecast (2017-2030)
10.1.10. Others
10.1.10.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cancer Therapeutics and Biotherapeutics Market, By Top Selling Drugs Type
11.1. Cancer Therapeutics and Biotherapeutics Market, by Top Selling Drugs Type, 2022-2030
11.1.1. Revlimid
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Avastin
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Herceptin
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Rituxan
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Opdivo
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Cancer Therapeutics and Biotherapeutics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.2. Market Revenue and Forecast, by End User (2017-2030)
12.1.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.1.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.5.2. Market Revenue and Forecast, by End User (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.2. Market Revenue and Forecast, by End User (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.2. Market Revenue and Forecast, by End User (2017-2030)
12.2.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.2.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.5.2. Market Revenue and Forecast, by End User (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.2. Market Revenue and Forecast, by End User (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.2. Market Revenue and Forecast, by End User (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.2. Market Revenue and Forecast, by End User (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.2. Market Revenue and Forecast, by End User (2017-2030)
12.3.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.3.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.5.2. Market Revenue and Forecast, by End User (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.2. Market Revenue and Forecast, by End User (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.2. Market Revenue and Forecast, by End User (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.2. Market Revenue and Forecast, by End User (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.2. Market Revenue and Forecast, by End User (2017-2030)
12.4.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.4.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.5.2. Market Revenue and Forecast, by End User (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.2. Market Revenue and Forecast, by End User (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.2. Market Revenue and Forecast, by End User (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.2. Market Revenue and Forecast, by End User (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.2. Market Revenue and Forecast, by End User (2017-2030)
12.5.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.5.2. Market Revenue and Forecast, by End User (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.2. Market Revenue and Forecast, by End User (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Application Type (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2017-2030)
Chapter 13. Company Profiles
13.1. Amgen Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bristol-Myers Squibb
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Celgene Corporation
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. ELI Lilly and Company
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Hoffmann-La Roche AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. EnGeneIC Ltd
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck & Co Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Pfizer Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1657
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments